FROM Aaron Kesselheim
An old drug gets a ridiculously high price….again Are incentives for so-called "orphan drugs" being misused to jack up the price of one medication by 4000 percent? Photo by Chris Potter A rare form of muscular dystrophy has long been treated in the US by a steroid imported from overseas at a price of $1200 a year. Now the FDA has approved its manufacture and distribution in this country by the drug company Marathon. The new price is $89,000 a year — reduced to $54,000 after rebates and discounts. We get perspective from Carolyn Johnson, who covers the business of medicine for the Washington Post , and Dr. Aaron Kesselheim, a professor of medicine at Harvard, where he's also Director of the program on Regulation, Therapeutics and Law.
Doctors, Drug Companies and Transparency In an effort to get doctors to prescribe their drugs to patients, drug makers spend billions of dollars a year on meals, speaking and consulting fees, and other perks for physicians. Today, a new government database goes online that will list the money pharmaceutical companies spend on doctors.
The Trump agenda: where's the beef? President Trump says big things are happening. After celebrating a House bill on health care, he doesn’t yet have Senate agreement. With James Comey’s public testimony scheduled tomorrow, the President today tweeted his selection of a new FBI Director. Is the Chief Executive all style and no substance? Later, terror attacks in Iran and conflicting claims about who’s behind them.
What happens when America retreats from the world? Is President Trump taking his "America First" agenda to extremes, withdrawing the country from the international stage on trade and climate change, distancing America from its traditional allies across the Atlantic and even threatening to physically isolate the country through the building of a wall along its southern border? León Krauze guest hosts.
Will the Senate write a healthcare bill in secret? While Democrats and Republicans argue White House relations with Russia, another question is being decided behind closed doors: who gets help buying health insurance and who doesn't? We hear how the pros and cons are being shrouded in secrecy.
Venezuela spirals into economic and political chaos Venezuela, a country whose potential for prosperity is unmatched, finds itself on the verge of civil war. What sustains the repressive government? With time running out, guest host León Krauze looks at what the international community can do to pull the country from the edge of collapse.